Connect Biopharma Holdings Ltd. is a global clinical-stage biopharmaceutical company focused on developing innovative therapies for T cell-driven inflammatory diseases. Headquartered in San Diego, California with operations in the United States and China, the company builds a pipeline of proprietary small molecules and antibodies using functional T cell assays to identify and validate therapeutic targets. Its lead product candidate, rademikibart, is an antibody targeting interleukin-4 receptor alpha currently in Phase 3 clinical development for atopic dermatitis and asthma. The company's second product candidate, icanbelimod, is an oral small molecule modulator of Sphingosine 1-Phosphate Receptor 1 in Phase 2 development for ulcerative colitis and Crohn's disease. Connect Biopharma aims to improve treatment outcomes for patients with chronic inflammatory conditions by leveraging advanced immunological research and targeted drug development strategies.